Brain Metastases News and Research

RSS

Whole brain radiotherapy offers no quality-of-life benefit in lung cancer patients with brain metastases

People with the most common type of lung cancer whose disease has spread to the brain could be spared potentially harmful whole brain radiotherapy, according to new research published in The Lancet.

6 Sep 2016

New combination treatment improves overall survival in patients with malignant melanoma

Among patients with melanoma, those who received both ipilimumab (Yervoy) and local peripheral treatments such as radiotherapy or electrochemotherapy had significantly prolonged overall survival compared with those who received only ipilimumab, according to a retrospective clinical study.

27 Jul 2016

Focused therapy may be effective, less toxic way to treat brain tumors

Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study that was accepted for publication by the Journal of the American Medical Association. The study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.

27 Jul 2016

Scientific paper supports concept of CarThera's intracranial ultrasound implant to disrupt blood-brain barrier

CarThera, a French company based at the Brain and Spine Institute, that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces the publication in Science Translational Medicine of a scientific paper on initial successes in disrupting the blood-brain barrier (BBB) with the use of ultrasound.

20 Jun 2016

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

23 May 2016

Inhibiting adrenaline receptors reduces breast cancer brain metastases

While we look to invent new medicines to treat cancer, a parallel approach to repurpose existing medicines may be highly effective. Stress, mediated by adrenaline, has been suspected to promote cancer growth and this research study shows that by blocking adrenaline receptors in breast cancers, they are less successful in spreading to and growing in the brain.

19 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

While two advanced radiosurgery approaches — Gamma Knife and RapidArc — offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center.

24 Feb 2016

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

11 Dec 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Discovery may lead to new anti-metastasis therapies for advanced-stage brain cancer patients

It's no surprise that people enjoy warm places like Hawaii but may suffer in hostile locales such as Antarctica. A tumor suppressor gene called PTEN is similar in that it is affected by the microenvironments of certain bodily organs to which it travels.

20 Oct 2015

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified a subset of those patients with a rare genetic mutation who are living significantly longer than patients without the mutation.

16 Oct 2015

Brain metastases evolve ‘clinically actionable’ mutations

Brain metastatic disease shows branched evolution from the primary tumour, suggest preliminary findings from the largest massively parallel sequencing study of paired samples performed so far.

7 Oct 2015

Certain laboratory results can help to predict survival in patients with brain metastases

A new MedUni Vienna study conducted in the Comprehensive Cancer Centre (CCC) Vienna shows that certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.

26 Sep 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

WBRT associated with worse cognitive function than radiosurgery, shows study

Whole Brain Radiation Therapy (WBRT) is associated with significantly worse cognitive function than radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery to treat cancer patients with brain metastases, according to a large study led by a researcher at The University of Texas MD Anderson Cancer Center.

1 Jun 2015

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Brain Metastases News and Research

Whole brain radiotherapy offers no quality-of-life benefit in lung cancer patients with brain metastases

New combination treatment improves overall survival in patients with malignant melanoma

Focused therapy may be effective, less toxic way to treat brain tumors

Scientific paper supports concept of CarThera's intracranial ultrasound implant to disrupt blood-brain barrier

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Inhibiting adrenaline receptors reduces breast cancer brain metastases

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Discovery may lead to new anti-metastasis therapies for advanced-stage brain cancer patients

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Brain metastases evolve ‘clinically actionable’ mutations

Certain laboratory results can help to predict survival in patients with brain metastases

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

WBRT associated with worse cognitive function than radiosurgery, shows study

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News